4.7 Article

Reduced Antinociception of Opioids in Rats and Mice by Vaccination with Immunogens Containing Oxycodone and Hydrocodone Haptens

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 56, 期 3, 页码 915-923

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm3013745

关键词

-

资金

  1. NIH NIDA [DA026300]
  2. Minneapolis Medical Research Foundation

向作者/读者索取更多资源

Prescription opioids abuse and associated deaths are an emerging concern in the USA. Vaccination against prescription opioids may provide an alternative to pharmacotherapy. An oxycodone hapten containing a tetraglycine linker at the C6 position (60XY(Gly)(4)OH) conjugated to keyhole limpet hemocyanin (KLH) has shown early proof-of-efficacy in rodents as a candidate immunogen (60XY(Gly)(4)-KLH) for the treatment of oxycodone abuse. In this study, oxycodone-based and hydrocodone-based haptens were conjugated to KLH to generate immunogens that would recognize both oxycodone and hydrocodone. Vaccination with 60XY(Gly)(4)-KLH increased drug binding in serum, reduced drug distribution to brain, and blunted analgesia for both oxycodone and hydrocodone. An analogous C6-linked hydrocodone vaccine blocked hydrocodone effects but less so than 60XY(Gly)(4)-KLH. C8-Linked hydrocodone immunogens had only limited efficacy. Amide conjugation showed higher haptenation ratios and greater efficacy than thioether conjugation to maleimide activated KLH (mKLH). The 60XY(Gly)(4)-KLH vaccine may be used for treatment of prescription opioid abuse.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity

Michael D. Raleigh, Claudia Accetturo, Marco Pravetoni

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Article Pharmacology & Pharmacy

Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats

Carly Baehr, April Huseby Kelcher, Aaron Khaimraj, Dana E. Reed, Sujata G. Pandit, David AuCoin, Saadyah Averick, Marco Pravetoni

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)

Article Immunology

Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders

Bethany Crouse, Christine Robinson, April Huseby Kelcher, Megan Laudenbach, Juan E. Abrahante, Marco Pravetoni

NPJ VACCINES (2020)

Article Immunology

Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge

Addison E. Stone, Sarah E. Scheuermann, Colin N. Haile, Gregory D. Cuny, Marcela Lopez Velasquez, Joshua P. Linhuber, Anantha L. Duddupudi, Jennifer R. Vigliaturo, Marco Pravetoni, Therese A. Kosten, Thomas R. Kosten, Elizabeth B. Norton

Summary: This study evaluated adjuvant and delivery strategies for vaccines targeting fentanyl, finding that dmLT or LTA1 adjuvants as well as mucosal delivery may be attractive strategies for improving the efficacy of vaccines against SUD.

NPJ VACCINES (2021)

Article Immunology

Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders

April M. Huseby Kelcher, Carly A. Baehr, Fatima A. Hamid, Geoffrey T. Hart, Marco Pravetoni

Summary: Vaccines and monoclonal antibodies show promise in treating substance use disorders and preventing overdose, with FcRn identified as playing a role in their efficacy. Phagocytosis or Fc-dependent effector functions are not required for the efficacy of vaccines and mAbs against SUD, according to this study.

JOURNAL OF IMMUNOLOGY (2021)

Article Biotechnology & Applied Microbiology

Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats

Bethany Crouse, Li Zhang, Christine Robinson, Yuguang Ban, Jennifer R. Vigliaturo, Sabita Roy, Marco Pravetoni

Summary: This study showed that housing mice and rats in either conventional or specific pathogen-free environment did not affect vaccine-induced antibody responses against oxycodone and fentanyl, nor their efficacy against oxycodone- and fentanyl-induced antinociception, respiratory depression, and bradycardia. Differences in the GI microbiome detected via 16S rRNA gene sequencing were related to the housing environment.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

Article Chemistry, Analytical

A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs

Leah M. Dignan, M. Shane Woolf, Jennifer A. Ross, Carly Baehr, Christopher P. Holstege, Marco Pravetoni, James P. Landers

Summary: This study introduces a portable centrifugal microfluidic ELISA system that replaces repetitive pipetting with rotationally controlled fluidics, allowing for sensitive and reliable colorimetric detection of opiates. This new approach could provide rapid and automatable drug detection outside of traditional laboratories by non-technical personnel.

ANALYTICAL CHEMISTRY (2021)

Article Pharmacology & Pharmacy

Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity

Carly A. Baehr, Mariah M. Wu, Sujata G. Pandit, Jose Arias-Umana, David AuCoin, Marco Pravetoni

Summary: The incidence of fatal drug overdoses in the US has increased due to the COVID-19 pandemic, with a significant portion attributed to fentanyl. A study has shown that the monoclonal antibody HY6-F9 can effectively reverse fentanyl-induced toxicity and protect against additional challenges. When used in combination with naloxone, the antibody provides greater protection. These findings support the use of monoclonal antibodies as medical interventions for fentanyl-related overdose prevention and reversal.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2022)

Article Chemistry, Multidisciplinary

Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl,Alfentanil, Sufentanil, and Acetylfentanyl in Rats

Carly Baehr, Christine Robinson, Andrew Kassick, Rajwana Jahan, Valeria Gradinati, Saadyah E. Averick, Scott P. Runyon, Marco Pravetoni

Summary: The ongoing public health emergency of opioid use disorders and overdose in the United States, driven by fentanyl and its analogues, calls for alternative interventions. A study compared different vaccines targeting fentanyl and its analogues and found that a lead conjugate vaccine was effective in reducing the pharmacological effects induced by these substances in rats.

ACS OMEGA (2022)

Article Biotechnology & Applied Microbiology

Advancing humanized monoclonal antibody for counteracting fentanyl toxicity towards clinical development

Dustin Hicks, Carly Baehr, Pedro Silva-Ortiz, Aaron Khaimraj, Diego Luengas, Fatima A. Hamid, Marco Pravetoni

Summary: Novel humanized anti-fentanyl monoclonal antibodies were developed and shown to effectively counteract the pharmacological effects of fentanyl, suggesting their potential for treating fentanyl toxicity.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Review Pharmacology & Pharmacy

Immunotherapeutic strategies for treating opioid use disorder and overdose

Rachel Luba, Suky Martinez, Jermaine Jones, Marco Pravetoni, Sandra D. Comer

Summary: This article provides an overview of the development and mechanisms of vaccines for substance use disorders. It focuses on existing preclinical and clinical trials and offers an expert opinion on the future work of vaccines for opioid use disorder. The authors emphasize the urgent need for effective treatments, including vaccines, to combat the current opioid crisis.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Editorial Material Pharmacology & Pharmacy

The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis

Suky Martinez, Hannah Harris, Thomas Chao, Rachel Luba, Marco Pravetoni, Sandra D. Comer, Jermaine D. Jones

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Article Chemistry, Medicinal

Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats

Bethany Crouse, Mariah M. Wu, Valeria Gradinati, Andrew J. Kassick, Daihyun Song, Rajwana Jahan, Saadyah Averick, Scott Runyon, Sandra D. Comer, Marco Pravetoni

Summary: The widespread availability of illicit fentanyl and other potent synthetic opioids has led to a significant increase in drug-related fatal overdoses over the past decade. Vaccination strategies that target carfentanil and fentanyl offer a promising approach to reducing fatalities associated with these substances and providing treatment for opioid use disorder. Preclinical studies have shown that mono- and bivalent vaccines can effectively protect against the pharmacological effects of carfentanil, fentanyl, and their mixtures.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

Article Chemistry, Medicinal

Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning

Andrew J. Kassick, Mariah Wu, Diego Luengas, Mohammad Ebqa'ai, L. P. Tharika Nirmani, Nestor Tomycz, Toby L. Nelson, Marco Pravetoni, Michael D. Raleigh, Saadyah Averick

Summary: This report describes a novel nanoparticle-based naloxone formulation that offers extended protection against the toxic effects of the synthetic opioid fentanyl. Pharmacokinetic evaluation revealed a significantly longer elimination half-life compared to high dose free naloxone in rats, and in vivo studies showed protection against fentanyl-induced respiratory depression and antinociception for up to 48 hours following a single injection. These findings support further investigation of this formulation as a potential therapeutic option for reversing opioid overdose and preventing renarcotization from potent opioids like fentanyl.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)

Article Nanoscience & Nanotechnology

Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone

Andrew J. Kassick, Heather N. Allen, Saigopalakrishna S. Yerneni, Fathima Pary, Marina Kovaliov, Cooper Cheng, Marco Pravetoni, Nestor D. Tomycz, Donald M. Whiting, Toby L. Nelson, Michael Feasel, Phil G. Campbell, Benedict Kolber, Saadyah Averick

ACS APPLIED BIO MATERIALS (2019)

暂无数据